title: DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
abstract: For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). This article addresses the relationship between DLB, PD, and PD with dementia (PDD). The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these disorders of alpha-synuclein metabolism. We concluded that the differing temporal sequence of symptoms and clinical features of PDD and DLB justify distinguishing these disorders. However, a single Lewy body disorder model was deemed more useful for studying disease pathogenesis because abnormal neuronal alpha-synuclein inclusions are the defining pathologic process common to both PDD and DLB. There was consensus that improved understanding of the pathobiology of alpha-synuclein should be a major focus of efforts to develop new disease-modifying therapies for these disorders. The group agreed on four important priorities: 1) continued communication between experts who specialize in PDD or DLB; 2) initiation of prospective validation studies with autopsy confirmation of DLB and PDD; 3) development of practical biomarkers for alpha-synuclein pathologies; 4) accelerated efforts to find more effective treatments for these diseases.
authors.affiliation: Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA. clippa@drexelmed.edu
authors.forename: C F
authors.initials: CF
authors.lastname: Lippa
authors.forename: J E
authors.initials: JE
authors.lastname: Duda
authors.forename: M
authors.initials: M
authors.lastname: Grossman
authors.forename: H I
authors.initials: HI
authors.lastname: Hurtig
authors.forename: D
authors.initials: D
authors.lastname: Aarsland
authors.forename: B F
authors.initials: BF
authors.lastname: Boeve
authors.forename: D J
authors.initials: DJ
authors.lastname: Brooks
authors.forename: D W
authors.initials: DW
authors.lastname: Dickson
authors.forename: B
authors.initials: B
authors.lastname: Dubois
authors.forename: M
authors.initials: M
authors.lastname: Emre
authors.forename: S
authors.initials: S
authors.lastname: Fahn
authors.forename: J M
authors.initials: JM
authors.lastname: Farmer
authors.forename: D
authors.initials: D
authors.lastname: Galasko
authors.forename: J E
authors.initials: JE
authors.lastname: Galvin
authors.forename: C G
authors.initials: CG
authors.lastname: Goetz
authors.forename: J H
authors.initials: JH
authors.lastname: Growdon
authors.forename: K A
authors.initials: KA
authors.lastname: Gwinn-Hardy
authors.forename: J
authors.initials: J
authors.lastname: Hardy
authors.forename: P
authors.initials: P
authors.lastname: Heutink
authors.forename: T
authors.initials: T
authors.lastname: Iwatsubo
authors.forename: K
authors.initials: K
authors.lastname: Kosaka
authors.forename: V M-Y
authors.initials: VM
authors.lastname: Lee
authors.forename: J B
authors.initials: JB
authors.lastname: Leverenz
authors.forename: E
authors.initials: E
authors.lastname: Masliah
authors.forename: I G
authors.initials: IG
authors.lastname: McKeith
authors.forename: R L
authors.initials: RL
authors.lastname: Nussbaum
authors.forename: C W
authors.initials: CW
authors.lastname: Olanow
authors.forename: B M
authors.initials: BM
authors.lastname: Ravina
authors.forename: A B
authors.initials: AB
authors.lastname: Singleton
authors.forename: C M
authors.initials: CM
authors.lastname: Tanner
authors.forename: J Q
authors.initials: JQ
authors.lastname: Trojanowski
authors.forename: Z K
authors.initials: ZK
authors.lastname: Wszolek
mesh_terms: D015415:Biomarkers / Q000378:metabolism*; D006801:Humans; D020961:Lewy Body Disease / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D010300:Parkinson Disease / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*
chemical_list: D015415:Biomarkers